BRAF and melanoma: In addition, treatment with atezolizumab and vemurafenib (a BRAF serine–threonine kinase inhibitor) with or without cobimetinib had higher response rates and faster and longer-lasting responses than cobimetinib plus vemurafenib or atezolizumab alone in previously untreated BRAFV600 mutation-positive advanced melanoma (17).